GERMANTOWN, MD--(Marketwired - Aug 17, 2016) - Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that Orgenesis management will present at the Cambridge Healthtech Institute's (CHI) 8th Annual Bioprocessing Summit, which is being held at the Westin Boston Waterfront hotel in Boston, Massachusetts from August 15 - 19. The Company's presentation, entitled Preparing for Commercialization -- The Orgenesis Story, will be held today, Wednesday, August 17, 2016 at 9:30 am in the Cell Therapy Bioproduction, Operations and Logistics track.
The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to share practical solutions for today's bioprocess challenges. Now in its eighth year, the event features 16 distinct meetings ranging from cell line development and ensuring quality, to formulation, analytical development, continuous processing, purification, viral clearance and safety, and bioproduction. New programming in 2016 will continue to expand the scope of the event and includes weeklong programming on cell and gene therapy production, and a meeting on manufacturing and CMC strategies for biologics. Along with the impressive array of conferences, the Summit also includes short courses and training seminars that provide in-depth coverage of critical bioprocess topics.
For more information on CHI's 8th Annual The Bioprocessing Summit, please visit: http://www.bioprocessingsummit.com/
About Orgenesis Inc.
Orgenesis is a fully integrated cell therapy and regenerative medicine company. The Company is providing manufacturing services for other cell therapy markets in such areas as cell-based cancer immunotherapies and autoimmune diseases. In addition, through its subsidiary, Orgenesis Ltd., the Company is developing a cure for diabetes using a novel "cellular trans-differentiation" technology that transforms an insulin-dependent patient's own adult cells into functional insulin producing cells. The Company has demonstrated that, when exposed ex-vivo to certain pancreatic transcription factors and in specific sequence, human adult cells can be transformed into fully functional, beta cell-like insulin producing cells. Orgenesis Ltd. has an exclusive license from Tel Hashomer Hospital for intellectual property directed to the cellular trans-differentiating technology.